Semaglutide, a GLP-1 receptor agonist drug, was originally developed as an anti-diabetic medication. It has now gained popularity for its significant results for weight loss. It mimics the action of ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

Medications that have transformed the treatment of obesity may also help people drink less alcohol, according to new government-funded research.

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

In a world where alcohol claims nearly 178,000 lives annually in the U.S. alone, a glimmer of hope has emerged from an ...

Semaglutide prescription initiation predictors included female sex and use of antidepressants among patients with obesity without diabetes.

A clinical trial shows that people who were considered by medical researchers to report signs of alcohol use disorder drank significantly less after taking semaglutide for two months, compared to ...

Can Roche bring a competitive GLP-1 to market to take on Lilly and Novo ... is showing its candidates are uncompetitive relative to semaglutide, tirzepatide, and a host of other clinical stage ...

Ashwin K. Chetty, from the Yale University School of Medicine in New Haven, Connecticut, and colleagues examined advertising practices of websites selling compounded GLP-1 RAs, including semaglutide, ...

"Because of the association of semaglutide with temporary worsening ... consulting on gastrointestinal adverse events with GLP-1 receptor agonists in litigation related to Ozempic (Novo Nordisk).

and the most commonly used agent was semaglutide (72.1%), followed by liraglutide (14.3%), and tirzepatide (13.6%). All patients had to have newly initiated a GLP-1 agent, a baseline body mass ...